Navigation Links
Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)
Date:5/18/2012

ted with Zysa experienced improvement in bloating and stool consistency. These improvements were lost when Zysa was replaced with placebo and regained when Zysa was reinstituted.

"Zysa is a locally acting, novel treatment for IBS that has been proven safe and well-tolerated. It has been shown to reduce pain and bloating for the short-term symptomatic treatment of IBS-d," stated Professor Jan Tack, Head of Clinic, Department of Gastroenterology in Leuven, Belgium and the lead investigator of the Zysa clinical trial. "Given the paucity of proven treatments for IBS-d, Zysa has the potential to become an important new tool for gastroenterologists working with patients to combat this very common disorder."

Ocera Therapeutics has received Fast Track status from the U.S. Food and Drug Administration (FDA) for Zysa for IBS-d and is planning to initiate further studies based on recent guidance and interactions with the FDA. Zysa is protected by patents for the short-term symptomatic relief of IBS-d until 2027. Currently, the only approved treatment in the U.S. for IBS-d is alosetron, which carries significant safety concerns that necessitate a risk minimization program. As such, most patients with non‐constipating IBS are treated with drugs that are either not indicated for IBS and are of unproven or limited efficacy in this population, including antispasmodic agents, antidepressants and probiotics [Brandt 2009; Hammerle 2008].

The CE Marking is a legally required mark for a product that is intended for sale in the European Market and declares the product complies with the essential requirements of the relevant European health, safety and environmental protection legislation. CE Marking certification was conducted by TUV SUD, a globally recognized testing, inspection and certification organization. 

About Zysa™ (spherical carbon adsorbent, AST-120)
Zysa is a novel proprietary spheric
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014  In part ... to leverage a hospital pharmacy as a strategic asset, ... national practice leader for Cardinal Health,s Innovation Delivery Solutions ... care can benefit both hospitals and patients. ... only one part of their job in a value-based ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Soft Tissue Repair Devices Market 2014-2018" report to ... the mass of cells that connect, support, or surround ... such as tendons, ligaments, cartilage, fascia, and other fibrous ... these tissues with age result in wear and tear ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Minn., Oct. 14 AbbeyMoor Medical Inc. ... CPT code by the American Medical Association (AMA) for ... action, effective in January 2010, upgrades The Spanner from ... Category I procedure code for established procedures. This major ...
... 14 CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH), provides ... in the company,s name, ticker symbol and CUSIP number. ... FINRA all documentation requested in connection with the name change, ... number for the company,s common shares. FINRA is working ...
Cached Medicine Technology:AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 2AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 3CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 "I had a ... of her crutches," said an inventor from Wetumpka, Ala. "In ... and sounds of the shore, I came up with a ... , She created a prototype for the patent-pending Deezers to ... enables the individual to use crutches, walkers, or canes at ...
(Date:8/30/2014)... 30, 2014 In today’s world, a ... difficult to get. Snoring and sleep apnea (a medical ... stops) robs people and their bed partners of the ... to 45% of the population snores and 20 million ... Of these, only 10% have been diagnosed and treated; ...
(Date:8/30/2014)... 30, 2014 The new review published by ... created by Karen Brimeyer, who wanted to make her guide ... This guide is now easy to find in the form ... this guide, the author of the new method shares all ... Daily Gossip writes in its review that the leaky gut ...
(Date:8/30/2014)... LiveStreamingFitness.com, a company dedicated to providing live ... resources, is proud to announce it has been recognized as ... fitness solutions by ABC’s Good Morning America. ... Good Morning America, “Live Streaming Fitness is the hottest new ... by streamlining your workout…to boot camp at Life Streaming Fitness ...
(Date:8/30/2014)... August 30, 2014 When a prominent bank ... as happened on Wednesday, August 27th, when news began surfacing ... JPMorgan Chase & Co and at least one other ... actually investigating attacks on seven prominent banks , everyone ... be affected, and the buzz quickly goes viral. Bloomberg ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5
... at Harvard University have created a laboratory model using ... stages of ovarian cancer metastasis. "We were ... for the force-dependent processes associated with metastasis," said Joan ... Harvard University. These findings are published in ...
... awarded Penn State, Penn State Milton S. Hershey Medical ... million, five-year grant designed to accelerate the translation of ... This competitive Clinical and Translational Science Award (CTSA) will ... (CTSI), a collaboration of many Penn State colleges and ...
... , TUESDAY, June 14 (HealthDay News) --,Scheduling classes later in ... in the morning, but it may also encourage them to ... that undergrads whose classes started later were more likely to ... times predicted more drinking, more sleep time and modestly lower ...
... liver fibrosis, such as liver stiffness measurement or the ... C, according to a new study in Gastroenterology ... (AGA) Institute. "Liver stiffness measurement and/or the ... hepatitis C, regardless of the stage of the disease," ...
... 15, the Lymphoma Research Foundation (LRF), in collaboration with ... Center, will bring together lymphoma experts to discuss the ... This event is the final installation of LRF,s 2010-2011 ... series focused on the diagnosis and treatment of lymphoma ...
... Tiny fibres used to strengthen everyday products such as bicycle ... involved in their manufacture. Certain types of carbon nanotubes ... human hair could cause cancer in the lining of ... study in mice found that while short carbon nanotubes appeared ...
Cached Medicine News:Health News:Penn State receives $27.3 million NIH grant 2Health News:Penn State receives $27.3 million NIH grant 3Health News:Penn State receives $27.3 million NIH grant 4Health News:College Students Who Sleep in Drink More, Study Less 2Health News:Noninvasive liver tests may predict hepatitis C patient survival 2Health News:Lymphoma Research Foundation and John Theurer Cancer Center collaborate for Lymphoma Rounds program 2
... while minimizing the pain of ... safety-engineered BD Microtainer Genie Lancet. ... offers a full range of ... blood collection and protects the ...
The DiaSTAT™ is an automated liquid chromatography system designed for the rapid and automated analysis of hemoglobin A1C. Ideal for low and ,medium volume testing environments....
The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia...
Inquire...
Medicine Products: